Gao, Xin
Zhang, Dachuan http://orcid.org/0000-0002-1746-275X
Xu, Chunliang http://orcid.org/0000-0002-4514-8477
Li, Huihui
Caron, Kathleen M.
Frenette, Paul S. http://orcid.org/0000-0003-0862-9922
Article History
Received: 4 November 2019
Accepted: 19 November 2020
First Online: 23 December 2020
Competing interests
: P.S.F. serves as consultant for Pfizer, has received research funding from Ironwood Pharmaceuticals and is a shareholder of Cygnal Therapeutics. The rest of the authors declare no competing interests.